Preview

The risk of developing a Clostridium difficile infection from the administration of different classes of antibiotics and their combinations to children in an oncological hospital

https://doi.org/10.18527/2500-2236-2020-7-1-54-58

Полный текст:

Аннотация

Patients in pediatric oncological hospitals are at risk of developing a Clostridium difficile infection. The purpose of this study was to determine the risk of developing a Clostridium difficile infection in patients who are treated with antibiotics of different classes and their combinations by way of a retrospective analysis of 122 patient records. It was shown that the administration of antibacterial chemotherapeutic drugs that belong to the classes of nitrofurans (enterofuryl), sulfonamides (biseptol), cephalosporins, and macrolides/azalides significantly increased the risk of developing a Clostridium difficile infection in pediatric patients. On the contrary, treatment with antibiotics of different classes, such as linezolid, colistin, and metronidazole, significantly reduced the risk of developing a Clostridium difficile infection. The use of penicillins, aminoglycosides, fluoroquinolones, glycopeptides, and carbapenems was not associated with the risk of developing a Clostridium difficile infection in pediatric patients. The administration of one or two antimicrobial drugs of different classes increased the risk of developing a Clostridium difficile infection while a combination of three different types of antimicrobial drugs lowered the rate of this infection in pediatric patients.

Об авторах

M. G. Shvydkaya
G. N. Gabrichevsky research institute for epidemiology and microbiology, Rospotrebnadzor
Россия

Maria Shvydkaya 


Moscow



A. M. Zatevalov
G. N. Gabrichevsky research institute for epidemiology and microbiology, Rospotrebnadzor
Россия

Moscow



D. T. Dzhandarova
Diagnostic Clinical Center No. 1
Россия

Moscow



S. D. Mitrokhin
City Clinical Hospital No. 67 named after L. A. Vorokhobov
Россия

Moscow



Список литературы

1. Lin HJ, Hung YP, Liu HC, Lee JC, Lee CI, Wu YH, et al. Risk factors for Clostridium difficile-associated diarrhea among hospitalized adults with fecal toxigenic C. difficile colonization. J Microbiol Immunol Infect 2015; 48(2), 183-9. doi: 10.1016/j.jmii.2013.08.003.

2. Czepiel J, Drozdz M, Pituch H, Kuijper EJ, Perucki W, Mielimonka A, et al. Clostridium difficile infection: review. Eur J Clin Microbiol Infect Dis 2019; 38(7), 1211-21. doi: 10.1007/s10096-019-03539-6.

3. Kelly CP, LaMont JT. Clostridium difficile – more difficult than ever. N Engl J Med 2008; 359(18), 1932-40. doi: 10.1056/NEJMra0707500.

4. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, et al. Burden of Clostridium difficile infection in the United States. N Engl J Med 2015; 372(9), 825-34. doi: 10.1056/NEJMoa1408913.

5. Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med 1994; 330(4), 257-62. doi: 10.1056/NEJM199401273300406.

6. Huelsenbeck J, Dreger SC, Gerhard R, Fritz G, Just I, Genth H. Upregulation of the immediate early gene product RhoB by exoenzyme C3 from Clostridium limosum and toxin B from Clostridium difficile. Biochemistry 2007; 46(16), 4923-31. doi: 10.1021/bi602465z.

7. Taur Y, Pamer EG. Harnessing microbiota to kill a pathogen: Fixing the microbiota to treat Clostridium difficile infections. Nat Med 2014; 20(3), 246-7. doi: 10.1038/nm.3492.

8. Ofori E, Ramai D, Dhawan M, Mustafa F, Gasperino J, Reddy M. Community-acquired Clostridium difficile: epidemiology, ribotype, risk factors, hospital and intensive care unit outcomes, and current and emerging therapies. J Hosp Infect 2018; 99(4), 436-42. doi: 10.1016/j.jhin.2018.01.015.

9. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficileassociated diarrhea with high morbidity and mortality. N Engl J Med 2005; 353(23), 2442-9. doi: 10.1056/NEJMoa051639.

10. Hautmann MG, Hipp M, Kolbl O. Clostridium difficile-associated diarrhea in radiooncology: an underestimated problem for the feasibility of the radiooncological treatment? Radiat Oncol 2011; 6, 89. doi: 10.1186/1748-717X-6-89.

11. Rodriguez Garzotto A, Merida Garcia A, Munoz Unceta N, Galera Lopez MM, Orellana-Miguel MA, Diaz-Garcia CV, et al. Risk factors associated with Clostridium difficile infection in adult oncology patients. Support Care Cancer 2015; 23(6), 1569-77. doi: 10.1007/s00520-014-2506-7.

12. Anand A, Glatt AE. Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis 1993; 17(1), 109-13. doi: 10.1093/clinids/17.1.109.

13. Lehrnbecher T, Fisher BT, Phillips B, Alexander S, Ammann RA, Beauchemin M, et al. Guideline for Antibacterial Prophylaxis Administration in Pediatric Cancer and Hematopoietic Stem Cell Transplantation. Clin Infect Dis 2020; 71(1), 226-36. doi: 10.1093/cid/ciz1082.

14. Eze P, Balsells E, Kyaw MH, Nair H. Risk factors for Clostridium difficile infections – an overview of the evidence base and challenges in data synthesis. J Glob Health 2017; 7(1), 010417. doi: 10.7189/jogh.07.010417.

15. Kumar M, Adhikari S, Hurdle JG. Action of nitroheterocyclic drugs against Clostridium difficile. Int J Antimicrob Agents 2014; 44(4), 314-9. doi: 10.1016/j.ijantimicag.2014.05.021.

16. Zakharova IN, Berezhnaya IV, Mumladze EB. Antibiotic-associated diarrhea in children: how to identify, what to do, how to treat? Medical Council 2016; 1(1), 78-89. doi: 10.21518/2079-701X-2016-1-78-89. (In Russian)

17. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69(4), 881-91. doi: 10.1093/jac/dkt477.

18. Deshpande A, Pasupuleti V, Thota P, Pant C, Rolston DD, Sferra TJ, et al. Community-associated Clostridium difficile infection and antibiotics: a meta-analysis. J Antimicrob Chemother 2013; 68(9), 1951-61. doi: 10.1093/jac/dkt129.

19. Vardakas KZ, Trigkidis KK, Boukouvala E, Falagas ME. Clostridium difficile infection following systemic antibiotic administration in randomised controlled trials: a systematic review and meta-analysis. Int J Antimicrob Agents 2016; 48(1), 1-10. doi: 10.1016/j.ijantimicag.2016.03.008.

20. Valerio M, Pedromingo M, Munoz P, Alcala L, Marin M, Pelaez T, et al. Potential protective role of linezolid against Clostridium difficile infection. Int J Antimicrob Agents 2012; 39(5), 414-9. doi: 10.1016/j.ijantimicag.2012.01.005.

21. Pereira JB, Farragher TM, Tully MP, Jonathan Cooke J. Association between Clostridium difficile infection and antimicrobial usage in a large group of English hospitals. Br J Clin Pharmacol 2014; 77(5), 896-903. doi: 10.1111/bcp.12255.

22. Shelygin YA, Alyoshkin VA, Sukhina MA, Mironov A Yu, Briko NI, Kozlov RS et al. Clinical guidelines for the diagnosis, treatment and prevention of Clostridium difficile-associated diarrhea (CDI). Clinical guidelines. Moscow: Remedium Volga region; 2019 (In Russian).

23. Banawas SS. Clostridium difficile Infections: A Global Overview of Drug Sensitivity and Resistance Mechanisms. Biomed Res Int 2018; 2018, 8414257. doi: 10.1155/2018/8414257.

24. Lopes Cancado GG, Silveira Silva RO, Rupnik M, Nader AP, Starling de Carvalho J, Miana de Mattos Paixao G, et al. Clinical epidemiology of Clostridium difficile infection among hospitalized patients with antibiotic-associated diarrhea in a university hospital of Brazil. Anaerobe 2018; 54, 65-71. doi: 10.1016/j.anaerobe.2018.08.005.


Для цитирования:


Shvydkaya M.G., Zatevalov A.M., Dzhandarova D.T., Mitrokhin S.D. The risk of developing a Clostridium difficile infection from the administration of different classes of antibiotics and their combinations to children in an oncological hospital. Microbiology Independent Research Journal (MIR Journal). 2020;7(1):54-58. https://doi.org/10.18527/2500-2236-2020-7-1-54-58

For citation:


Shvydkaya M.G., Zatevalov A.M., Dzhandarova D.T., Mitrokhin S.D. The risk of developing a Clostridium difficile infection from the administration of different classes of antibiotics and their combinations to children in an oncological hospital. Microbiology Independent Research Journal (MIR Journal). 2020;7(1):54-58. https://doi.org/10.18527/2500-2236-2020-7-1-54-58

Просмотров: 27


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2500-2236 (Online)